Recombinant anti-mouse gp75 antibody
Product | Unit size | Cat. code | Docs. | Qty. | Price | |
---|---|---|---|---|---|---|
Anti-mgp75-mIgG2a InvivoFit™ TA99-derived mouse monoclonal antibody against gp75/TYRP1 |
Show product |
1 mg 10 mg |
mgp75-mab10-1
|
Recombinant mouse gp75 antibody for in vivo use
InvivoGen’s Anti-mgp75-mIgG2a is free of aberrant light chains
Anti-mgp75-mIgG2a InvivoFit™ is a recombinant mouse IgG2a monoclonal antibody (mAb) based on the previously described clone TA99. This clone reacts against the human and mouse tumor-associated antigen antigen glycoprotein 75 (gp75) [1]. The sequence of Anti-mgp75-mIgG2a InvivoFit™ is 100% murine (constant and variable regions), thus ensuring minimal immunogenicity upon repeated injections into mice. This mAb efficiently induces protective immunity against B16F10 melanoma, either subcutaneous or metastatic [2]. Of note, the mIgG2a isotype was shown to be the most potent at inducing antibody-dependent cellular cytotoxicity compared to mIgG1, mIgG2b, and mIgG3 [3]. As opposed to the original hybridoma-based production which contains a mixed population of anti-gp75 antibodies featuring correct or aberrant light chains [4], InvivoGen produces the recombinant anti-mgp75-mIgG2a mAb using Chinese hamster ovary (CHO) cells.
Anti-mgp75-mIgG2a is purely monoclonal and is provided in an InvivoFit™ grade, a high-quality standard specifically adapted to in vivo studies.
Key features of Anti-mgp75-mIgG2a InvivoFit™:
- Sequence is 100% murine
- Free from non-relevant mAbs found in hybridoma-based productions
- Filter-sterilized (0.2 µm), endotoxin level < 1 EU/mg
- Suitable for parenteral delivery in mice (azide-free)
- Low aggregation < 5%
- Produced in animal-free facilities and defined media
Anti-mgp75-mIgG2a InvivoFit™ is purified by affinity chromatography with protein A. Its binding to mouse gp-75 is validated using ELISA.
References:
1. Thomson T.M. et al., 1985. Pigmentation-associated glycoprotein of human melanomas and melanocytes: definition with a mouse monoclonal antibody. J Invest Dermatol. 85(2):169-74.
2. Hara I. et al., 1995. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med. 182(5):1609-14.
3. Nimmerjahn F. & Ravetch J.V., 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 310(5753):1510-2.
4. Boross P. et al., 2014. Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice. Immunol Lett. 160(2):151-7.
Specifications
Specificity: Targets cells expressing murine gp75
Formulation: Lyophilized from 0.2 μm filtered solution in 150 mM sodium chloride, 20 mM sodium phosphate buffer with 5% saccharose
Clonality: Monoclonal antibody
Isotype: Murine IgG2a, kappa
Control: mIgG2a InvivoFit™ isotype control
Source: CHO cells
Clone: TA99
Purity: Purified by affinity chromatography with protein A
Tested applications: ELISA
Quality control:
- Binding confirmed using ELISA
- The complete sequence of this antibody has been verified
- < 5% aggregates (confirmed by size exclusion chromatography)
- Endotoxin level <1 EU/mg (determined by the LAL assay)
Contents
Anti-mgp75-mIgG2a InvivoFit™ is provided filter-sterilized (0.2 µm), endotoxin-free, azide-free, and lyophilized.
This product is available in two pack sizes:
- mgp75-mab10-1 : 1 mg
- mgp75-mab10-10 : 10 mg
The product is shipped at room temperature.
Store lyophilized antibody at -20 °C.
Lyophilized product is stable for at least 1 year
Avoid repeated freeze-thaw cycles.
Back to the topInvivoFit™
InvivoFit™ is a high-quality standard specifically adapted for in vivo studies. InvivoFit™ products are filter-sterilized (0.2 µm) and filled under strict aseptic conditions in a clean room. The level of bacterial contaminants (endotoxins and lipoproteins) in each lot is verified using a LAL assay and a TLR2 and TLR4 reporter assay.
Back to the topDetails
Glycoprotein 75 (gp75) is a tumor-associated antigen specifically located within the membrane of melanosomes; the organelles producing melanin in melanocytes. This 75-kDa polypeptide is the mature form of tyrosinase-related protein 1 (TYRP1; also known as MEL-5).
This enzyme is the most abundant glycoprotein synthesized by pigmented melanocytes and melanomas. It is involved in melanin synthesis as well as the proliferation and cell death of melanocytes. Importantly, gp75 is a target of choice for antibody-based immunotherapy against primary and metastatic melanoma.